Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.63 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670912 | 1.00 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11SLC6A2 | |
| SCHEMBL6688817 | 0.81 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6700816 | 0.77 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6700819 | 0.77 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6865819 | 0.76 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6867067 | 0.75 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6668401 | 0.74 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6666980 | 0.73 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6866863 | 0.73 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11 | |
| Hydrochloric Acid SCHEMBL6672197 | 0.72 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809199-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | MERCK & CO., INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1345603-A4 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1345603-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | Merck & Co., Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MAPK1, MAPK7, MAPKAPK2 | MAPK14 5/4885MAPK13 11/4885MAPK12 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.